Pharmaceutical Intermediate CAS 137234-62-9 Voriconazole Antifungal Voriconazole Powder Purity Voriconazole

• Customization: Available
• CAS No.: 137234-62-9
• Formula: C16h14f3n5o
• Model NO.: QS-Voriconazole
• EINECS: 629-701-5
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: 2 Years
• Nutrient Composition: Voriconazole
• Resource: Voriconazole
• The content of active substances: 99%
• Product Name: Voriconazole
• Name: Voriconazole Powder
• Appearance: White to Almost White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediates
• Specific: COA
• Test Method: HPLC
• Mf: C16h14f3n5o
• MW: 349.317
• Density: 1.42
• Melting Point: 127-130 C
• Boiling Point: 508.6 C at 760 Mmhg
• Logp: 2.17690
• Pka: 11.54±0.29(Predicted)
• Transport Package: Negotiable
• Specification: 99%
• Trademark: QS
• Origin: Shaanxi
• Production Capacity: 5 Ton/Month

Product Description

Pharmaceutical Intermediate CAS 137234-62-9 Voriconazole Antifungal Voriconazole Powder Purity Voriconazole

Product Description

Product Detials

Product Name	Voriconazole
Apperance	White powder
CAS	137234-62-9
MF	C16H14F3N5O
MW	349.317

Voriconazole Tablets, this product is a broad-spectrum triazole antifungal drug. Its indications are as follows: treatment of invasive aspergillosis. For the treatment of severe invasive infections caused by fluconazole-resistant Candida (including Candida cribrosa). Treat severe infections caused by Actinomycetes and Fusarium. This product should mainly be used for the treatment of progressive and potentially life-threatening infections in immunodeficient patients. This medicine is classified under the category of other antibacterial and anti-inflammatory drugs.

Application&Function

Purpose
Antifungal drugs

Broad-spectrum antifungal

Voriconazole [137234-62-9] belongs to the second-generation triazole antifungal drugs and is a raw material for preparations of infectious diseases. It has a broad antibacterial spectrum, strong antibacterial activity and good oral absorption, and is a new drug for the clinical treatment of fungal diseases. It is mainly used to treat invasive Aspergillus disease, severe invasive infections caused by fluconazole-resistant Candida, and severe infections caused by Actinomycetes and Fusarium. It is also applicable to the treatment of progressive and potentially life-threatening infections in immunodeficient patients. The mechanism of action of voriconazole is to inhibit the 14α -sterol demethylation mediated by cytochrome P450 in fungi, thereby inhibiting the biosynthesis of ergosterol. 

Specification

Certificate of Analysis